Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Retained Earnings (2016 - 2025)

Corcept Therapeutics' Retained Earnings history spans 10 years, with the latest figure at $643.4 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 296591.71% year-over-year to $643.4 million; the TTM value through Dec 2025 reached $643.4 million, up 296591.71%, while the annual FY2025 figure was $643.4 million, 296591.71% up from the prior year.
  • Retained Earnings for Q4 2025 was $643.4 million at Corcept Therapeutics, up from $619.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $643.4 million in Q4 2025 and bottomed at -$2.4 million in Q3 2022.
  • The 5-year median for Retained Earnings is $175.1 million (2021), against an average of $214.3 million.
  • The largest annual shift saw Retained Earnings tumbled 2170.43% in 2022 before it skyrocketed 296591.71% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$227000.0 in 2021, then tumbled by 282.82% to -$869000.0 in 2022, then surged by 46420.6% to $402.5 million in 2023, then plummeted by 100.05% to -$217000.0 in 2024, then surged by 296591.71% to $643.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Retained Earnings are $643.4 million (Q4 2025), $619.1 million (Q3 2025), and $2.3 million (Q2 2025).